Cipla在26财政年度第2季度利润增长3.7%,收入创纪录,原因是呼吸道毒品需求强劲,新产品推出,CEO变更,Eli Lilly建立了新的伙伴关系。 Cipla posted a 3.7% profit rise and record revenue in Q2 FY26, driven by strong respiratory drug demand and new product launches, with a CEO change and new Eli Lilly partnership.

Cipla报告说,由于印度呼吸道药物需求强劲和慢性疾病供应增加,同比年利润增长3.7%,达到1 351克朗,创纪录的收入在26财政年度第2季度达到7 589克朗。 Cipla reported a 3.7% year-on-year profit increase to ₹1,351 crore and record revenue of ₹7,589 crore in Q2 FY26, driven by strong respiratory drug demand in India and expanding chronic disease offerings. 该公司实现了25%的EBITDA利率,推出了包括在骨科护理中的六种新产品,并通过生物类似药的推出和FDA设施批准加强了其在美国的存在. The company achieved a 25% EBITDA margin, launched six new products including in orthocare, and strengthened its U.S. presence with a biosimilar launch and FDA facility approval. 已宣布改变领导地位,阿钦古普塔定于2026年4月接替乌曼·沃赫拉担任首席执行官。 Leadership changes were announced, with Achin Gupta set to succeed Umang Vohra as CEO in April 2026. Cipla还与Eli Lilly合作在印度分发一种通用的tirzepatide。 Cipla also partnered with Eli Lilly to distribute a generic tirzepatide in India. 尽管取得了结果,但份额略有下降。 Despite results, shares declined slightly.